Urokinase plasminogen activator (uPA) is a serine protease causally involved in cancer invasion and metastasis. Consistent with its role in cancer spread, uPA has been shown to be a prognostic marker in a variety of malignancies, especially breast cancer. Approximately 20 different groups have shown
The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer
โ Scribed by Yoshihiro Hasui; Kousuke Marutsuka; Junji Suzumiya; Shinichiro Kitada; Yukio Osada; Akinobu Sumiyoshi
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- French
- Weight
- 369 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
โฆ Synopsis
Urokinase
-type plasminogen activator (u-PA) is thought to be implicated in cancer invasion and metastasis. The aim of this study was to determine whether the u-PA content of cancer tissue is a prognostic factor in bladder cancer. Tissue samples from 46 patients with bladder cancer were assessed for u-PA antigen by a highly sensitive enzyme immunoassay. The relationships between the u-PA level in extracts of bladder cancer and the survival rates of the bladder-cancer patients were examined. Patients with a high u-PA level (8 ng/mg of protein and more) showed a statistically significantly higher rate of survival than those with a low u-PA level (p < 0.005). The u-PA antigen level in cancer tissue was significantly lower in low-graded and non-invasive cancers than in others (p < 0.01).
๐ SIMILAR VOLUMES
## Background: The authors found previously that plasma levels of urokinase-type plasminogen activator (upa) and its receptor (upar) were elevated in patients with bladder carcinoma and were associated with features of biologically aggressive disease. in the current study, they tested the hypothesi
Tumor recurrence is a common problem in the treatment of breast cancer. In breast cancer, the expression of high protein levels of the insulin-like growth factor-1 receptor (IGF-1R) and urokinase-type plasminogen activator-1 (uPA) is strongly associated with breast cancer recurrence and decreased su